HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.

Abstract
Prostate cancer mortality is primarily attributed to metastatic rather than primary, organ-confined disease. Acquiring a motile and invasive phenotype is an important step in development of tumors and ultimately metastasis. This step involves remodeling of the extracellular matrix and of cell-matrix interactions, cell movement mediated by the actin cytoskeleton, and activation of focal adhesion kinase (FAK)/Src signaling. Epidemiologic studies suggest that the metastatic behavior of prostate cancer may be an ideal target for chemoprevention. The natural flavone apigenin is known to have chemopreventive properties against many cancers, including prostate cancer. Here, we study the effect of apigenin on motility, invasion, and its mechanism of action in metastatic prostate carcinoma cells (PC3-M). We found that apigenin inhibits PC3-M cell motility in a scratch-wound assay. Live cell imaging studies show that apigenin diminishes the speed and affects directionality of cell motion. Alterations in the cytoskeleton are consistent with impaired cell movement in apigenin-treated cells. Apigenin treatment leads to formation of "exaggerated filopodia," which show accumulation of focal adhesion proteins at their tips. Furthermore, apigenin-treated cells adhere more strongly to the extracellular matrix. Additionally, apigenin decreases activation of FAK and Src, and phosphorylation of Src substrates FAK Y576/577 and Y925. Expression of constitutively active Src blunts the effect of apigenin on cell motility and cytoskeleton remodeling. These results show that apigenin inhibits motility and invasion of prostate carcinoma cells, disrupts actin cytoskeleton organization, and inhibits FAK/Src signaling. These studies provide mechanistic insight into developing novel strategies for inhibiting prostate cancer cell motility and invasiveness.
AuthorsCarrie A Franzen, Evangeline Amargo, Viktor Todorović, Bhushan V Desai, Sabil Huda, Salida Mirzoeva, Karen Chiu, Bartosz A Grzybowski, Teng-Leong Chew, Kathleen J Green, Jill C Pelling
JournalCancer prevention research (Philadelphia, Pa.) (Cancer Prev Res (Phila)) Vol. 2 Issue 9 Pg. 830-41 (Sep 2009) ISSN: 1940-6215 [Electronic] United States
PMID19737984 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Actins
  • Apigenin
  • Focal Adhesion Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins pp60(c-src)
Topics
  • Actins (metabolism, ultrastructure)
  • Apigenin (pharmacology)
  • Cell Adhesion (drug effects)
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cytoskeleton (drug effects, ultrastructure)
  • Enzyme Activation (drug effects)
  • Fluorescent Antibody Technique
  • Focal Adhesion Protein-Tyrosine Kinases (metabolism)
  • Humans
  • Immunoblotting
  • Male
  • Prostatic Neoplasms (drug therapy, metabolism, pathology)
  • Proto-Oncogene Proteins pp60(c-src) (metabolism)
  • Pseudopodia (drug effects)
  • Signal Transduction
  • Transfection
  • Tumor Cells, Cultured
  • Wound Healing (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: